Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReFacto AF in hemophilia A patients undergoing elective major surgery
2005-001579-37Phase 3Terminated
- Sponsor
- Wyeth
- Start
- Dec 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human coagulation factor VIII in hemophilia A (2 arms), sponsored by Wyeth. Primary endpoint: Hemostatic efficacy at end of surgery. Started Dec 2005; status: terminated.
02
Drugs
recombinant human coagulation factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2005-001579-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001579-37.